Keyphrases
Acute Heart Failure
100%
Randomized Clinical Trial
100%
Spironolactone
100%
ATHENA
100%
Usual Care
75%
High Dose
75%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
62%
Congestion
37%
Placebo
25%
No Significant Difference
12%
Renal Function
12%
Worse Outcome
12%
Estimated Glomerular Filtration Rate
12%
Left Ventricular Ejection Fraction
12%
Heart Failure Hospitalization
12%
Acute Hospital
12%
Weight Change
12%
All-cause Mortality
12%
Serum Potassium
12%
Urine Output
12%
B-type Natriuretic Peptide
12%
Mineralocorticoid Receptor Antagonists
12%
Hyperkalemia
12%
Diuretic Resistance
12%
Hospitalization Rate
12%
Hispanic or Latino
12%
Net Weight
12%
Other-race
12%
Neurohormonal Activation
12%
Dyspnea
12%
Race-ethnicity
12%
Output Weights
12%
Ejection Fraction
12%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Clinical Trial
100%
Spironolactone
100%
Acute Heart Failure
100%
Brain Natriuretic Peptide
75%
Placebo
25%
Congestive Heart Failure
12%
Isotopes of Potassium
12%
All Cause Mortality
12%
Hyperkalemia
12%
Mineralocorticoid Antagonist
12%
Dyspnea
12%
Diuretics
12%